A trade deal between the EU and Canada, due to be signed today (September 26) if last-minute German concerns can be overcome, would have implications for pharmaceutical IP protection and could raise the cost of drugs in Canada, a report has claimed.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
pharmaceutical, patent protection, Canada, EU